Pump.fun has extended its limit-order feature, previously available only on Solana, to six additional EVM-compatible networks: Robinhood, BSC, Base, HyperEVM, Arc, and Ink. This expansion allows users to set take-profit and stop-loss orders across multiple chains, enhancing cross-network trading capabilities. The app also supports token launches and in-chat transactions, with plans to add more chains in the future. This development broadens trading tools for users engaging in decentralized finance across diverse blockchain ecosystems.
Pump.fun's expansion of EVM limit orders across six blockchain networks provides context for decentralized finance tools. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 24, 2026 00:22 WIB: out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell today. Notable movers include Bitcoin Cash (BCH) at Rp5.166.767 with a 1-day change of +5.09%, VeChain (VET) at Rp132 with a 1-day change of +4.97%, and Terra Classic (LUNC) at Rp0,838 with a 1-day change of +3.29%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
